123 related articles for article (PubMed ID: 25460503)
1. ADAM10 and ADAM17: New players in trastuzumab tesistance.
Duffy MJ; Crown J; Mullooly M
Oncotarget; 2014 Nov; 5(22):10963-4. PubMed ID: 25460503
[No Abstract] [Full Text] [Related]
2. ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer.
Feldinger K; Generali D; Kramer-Marek G; Gijsen M; Ng TB; Wong JH; Strina C; Cappelletti M; Andreis D; Li JL; Bridges E; Turley H; Leek R; Roxanis I; Capala J; Murphy G; Harris AL; Kong A
Oncotarget; 2014 Aug; 5(16):6633-46. PubMed ID: 24952873
[TBL] [Abstract][Full Text] [Related]
3. Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells.
Liu PC; Liu X; Li Y; Covington M; Wynn R; Huber R; Hillman M; Yang G; Ellis D; Marando C; Katiyar K; Bradley J; Abremski K; Stow M; Rupar M; Zhuo J; Li YL; Lin Q; Burns D; Xu M; Zhang C; Qian DQ; He C; Sharief V; Weng L; Agrios C; Shi E; Metcalf B; Newton R; Friedman S; Yao W; Scherle P; Hollis G; Burn TC
Cancer Biol Ther; 2006 Jun; 5(6):657-64. PubMed ID: 16627989
[TBL] [Abstract][Full Text] [Related]
4. Effects of ADAM10 and ADAM17 Inhibitors on Natural Killer Cell Expansion and Antibody-dependent Cellular Cytotoxicity Against Breast Cancer Cells
Pham DH; Kim JS; Kim SK; Shin DJ; Uong NT; Hyun H; Yoon MS; Kang SJ; Ryu YJ; Cho JS; Yoon JH; Lee JS; Cho D; Lee SH; Park MH
Anticancer Res; 2017 Oct; 37(10):5507-5513. PubMed ID: 28982863
[TBL] [Abstract][Full Text] [Related]
5. ADAM10-mediated release of heregulin confers resistance to trastuzumab by activating HER3.
Ebbing EA; Medema JP; Damhofer H; Meijer SL; Krishnadath KK; van Berge Henegouwen MI; Bijlsma MF; van Laarhoven HW
Oncotarget; 2016 Mar; 7(9):10243-54. PubMed ID: 26863569
[TBL] [Abstract][Full Text] [Related]
6. Compelling P1 substituent affect on metalloprotease binding profile enables the design of a novel cyclohexyl core scaffold with excellent MMP selectivity and HER-2 sheddase inhibition.
Burns DM; Li YL; Shi E; He C; Xu M; Zhuo J; Zhang C; Qian DQ; Li Y; Wynn R; Covington MB; Katiyar K; Marando CA; Fridman JS; Scherle P; Friedman S; Metcalf B; Yao W
Bioorg Med Chem Lett; 2009 Jul; 19(13):3525-30. PubMed ID: 19457660
[TBL] [Abstract][Full Text] [Related]
7. The good, the bad and the ugly substrates for ADAM10 and ADAM17 in brain pathology, inflammation and cancer.
Pruessmeyer J; Ludwig A
Semin Cell Dev Biol; 2009 Apr; 20(2):164-74. PubMed ID: 18951988
[TBL] [Abstract][Full Text] [Related]
8. Identification of ADAM10 as a major TNF sheddase in ADAM17-deficient fibroblasts.
Mezyk-Kopeć R; Bzowska M; Stalińska K; Chełmicki T; Podkalicki M; Jucha J; Kowalczyk K; Mak P; Bereta J
Cytokine; 2009 Jun; 46(3):309-15. PubMed ID: 19346138
[TBL] [Abstract][Full Text] [Related]
9. Proteolytically active ADAM10 and ADAM17 carried on membrane microvesicles in human abdominal aortic aneurysms.
Folkesson M; Li C; Frebelius S; Swedenborg J; Wågsäter D; Williams KJ; Eriksson P; Roy J; Liu ML
Thromb Haemost; 2015 Nov; 114(6):1165-74. PubMed ID: 26422658
[TBL] [Abstract][Full Text] [Related]
10. ADAM10 as a target for anti-cancer therapy.
Moss ML; Stoeck A; Yan W; Dempsey PJ
Curr Pharm Biotechnol; 2008 Feb; 9(1):2-8. PubMed ID: 18289051
[TBL] [Abstract][Full Text] [Related]
11. ADAM10 and ADAM17 have opposite roles during sprouting angiogenesis.
Caolo V; Swennen G; Chalaris A; Wagenaar A; Verbruggen S; Rose-John S; Molin DG; Vooijs M; Post MJ
Angiogenesis; 2015 Jan; 18(1):13-22. PubMed ID: 25218057
[TBL] [Abstract][Full Text] [Related]
12. Etoposide induces apoptosis and upregulation of TACE/ADAM17 and ADAM10 in an in vitro male germ cell line model.
Lizama C; Ludwig A; Moreno RD
Biochim Biophys Acta; 2011 Jan; 1813(1):120-8. PubMed ID: 20800622
[TBL] [Abstract][Full Text] [Related]
13. Expression profile of ADAM10 and ADAM17 in allergic rhinitis.
Chueh HW; Park SK; Hur DY; Bae WY
Int Forum Allergy Rhinol; 2015 Nov; 5(11):1036-41. PubMed ID: 26250527
[TBL] [Abstract][Full Text] [Related]
14. Improved synthesis of ADAM10 inhibitor GI254023X.
Hoettecke N; Ludwig A; Foro S; Schmidt B
Neurodegener Dis; 2010; 7(4):232-8. PubMed ID: 20197648
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of ADAM 10 and ADAM 12 in lesional psoriatic skin.
Oh ST; Schramme A; Stark A; Tilgen W; Gutwein P; Reichrath J
Br J Dermatol; 2008 Jun; 158(6):1371-3. PubMed ID: 18363768
[No Abstract] [Full Text] [Related]
16. ADAM10 correlates with uveal melanoma metastasis and promotes in vitro invasion.
Gangemi R; Amaro A; Gino A; Barisione G; Fabbi M; Pfeffer U; Brizzolara A; Queirolo P; Salvi S; Boccardo S; Gualco M; Spagnolo F; Jager MJ; Mosci C; Rossello A; Ferrini S
Pigment Cell Melanoma Res; 2014 Nov; 27(6):1138-48. PubMed ID: 25124714
[TBL] [Abstract][Full Text] [Related]
17. Melatonin stimulates the nonamyloidogenic processing of βAPP through the positive transcriptional regulation of ADAM10 and ADAM17.
Shukla M; Htoo HH; Wintachai P; Hernandez JF; Dubois C; Postina R; Xu H; Checler F; Smith DR; Govitrapong P; Vincent B
J Pineal Res; 2015 Mar; 58(2):151-65. PubMed ID: 25491598
[TBL] [Abstract][Full Text] [Related]
18. The metalloproteinase-disintegrin ADAM10 is exclusively expressed by type I muscle fibers.
Dehmel T; Goebel HH; Hartung HP; Lehmann H; Wiendl H; Kieseier BC
Muscle Nerve; 2008 Aug; 38(2):1049-51. PubMed ID: 18642355
[TBL] [Abstract][Full Text] [Related]
19. The close link between retinoid signalling and the α-secretase ADAM10 and its potential for treating Alzheimer's disease (commentary on Jarvis et al.).
Fahrenholz F
Eur J Neurosci; 2010 Oct; 32(8):1245. PubMed ID: 20973156
[No Abstract] [Full Text] [Related]
20. Soluble T cell immunoglobulin and mucin domain (TIM)-1 and -4 generated by A Disintegrin And Metalloprotease (ADAM)-10 and -17 bind to phosphatidylserine.
Schweigert O; Dewitz C; Möller-Hackbarth K; Trad A; Garbers C; Rose-John S; Scheller J
Biochim Biophys Acta; 2014 Feb; 1843(2):275-87. PubMed ID: 24286866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
